Corvus Pharmaceuticals (CRVS) Cash & Current Investments (2015 - 2026)

Corvus Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $236.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 4635.23% year-over-year to $236.7 million; the TTM figure through Mar 2026 stood at $236.7 million (up 4635.23% YoY), while the FY2025 annual figure was $56.8 million, up 9.21% from the prior year.
• Cash & Current Investments was $236.7 million for Q1 2026 at Corvus Pharmaceuticals, up from $56.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $236.7 million in Q1 2026 to a low of $2.9 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $31.9 million across 5 years, with a median of $14.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments sank 79.26% in 2022, then soared 4635.23% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $13.2 million in 2022, then decreased by 4.1% to $12.6 million in 2023, then surged by 311.76% to $52.0 million in 2024, then advanced by 9.21% to $56.8 million in 2025, then jumped by 317.12% to $236.7 million in 2026.
• The last three Cash & Current Investments figures came in at $236.7 million (Q1 2026), $56.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.